Navigation Links
YM BioSciences reports second quarter 2010 operational and financial results
Date:2/8/2010

MISSISSAUGA, ON, Feb. 8 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE YMI, TSX: YM), today reported operational and financial results for the second quarter of fiscal 2010, ended December 31, 2009.

"After rigorous evaluation of numerous global in-licensing opportunities, we proposed to merge Cytopia Limited., a clinical-stage, Melbourne-based drug development company, into YM during the second quarter," said David Allan, Chairman & CEO of YM BioSciences Inc. "Cytopia products are an ideal complement to our current portfolio and this merger provides all shareholders both risk mitigation and a much enhanced prospect for success through the opportunity to link Cytopia's earlier stage products in development to our well-advanced development of nimotuzumab both directly and through our extensive network of international licensees. Subsequent to quarter-end, the merger was completed. The combination of YM and Cytopia is completely aligned with the YM business model to continuously renew our pipeline through additions of promising new drug candidates from the basic research of other organizations."

Highlights for the second quarter of Fiscal 2010:

    -   Signed agreement with Therapure Biopharma, under which it will
        formulate and fill nimotuzumab into sterile vials in its aseptic,
        GMP-certified, and Health Canada-licensed fill suite in Mississauga,
        Canada.

    -   Utilizing YM's IntelliMab(TM) technology, the collaboration between
        the National Research Council of Canada's Biotechnology Research
        Institute (NRC-BRI) and YM resulted in a number of antibodies that
        bind optimally to HER2/neu-over-expressing breast cancer cells while
        minimally binding to HER2 on normal cardiac cells.

    -   Cytopia 
'/>"/>
SOURCE  YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 

Related biology technology :

1. Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
2. Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results
3. Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
4. Cellectricon Files Patent Infringement Suit Against Fluxion Biosciences
5. YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA
6. YM BioSciences announces result of Cytopia shareholder vote
7. Profectus Biosciences to Present at Key Investor Conference in January 2010
8. David L. Macdonald Appointed CEO of GeneLink BioSciences, Inc.
9. YM BioSciences Inc. and Therapure Biopharma Inc. Announce Contract
10. Nu-Tek BioSciences, LLC. Launches Animal-Free, Non-GM Soy Peptone 
11. Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... and NEW ORLEANS , ... in the field of regenerative medicine, presented new data ... from Analysis Group (a leading health economics consultancy) demonstrating ... foot ulcers (DFU) and venous leg ulcers (VLU) place ... results of this research, which reveal annual costs of ...
(Date:5/22/2013)... Toronto, Ontario (PRWEB) May 22, 2013 ... of advanced sound therapy for tinnitus treatment. AudioNotch ... Destination Hearing . With clinic locations in both ... trusted provider of audiology and hearing services. AudioNotch's ... Zabell locations. , Upon entering a Destination Hearing ...
(Date:5/22/2013)... 2013 Alton Housing Authority was hit by ... said that their presence has already caused the company ... avoid such big spending, My Cleaning Products shared a way ... was said in the report that to clear the ... from that, its employees also attended a mandatory training on ...
(Date:5/22/2013)... May 22, 2013 The ability ... deciphering the information they encode. There are now ... (deep sequencing of ribosome protected fragments) that dramatically ... , Keynote speakers include Dr. Jonathan Weissman, an ... the Howard Hughes Medical Institute, who will present ...
Breaking Biology Technology:Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 2Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 3Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 4AudioNotch Tinnitus Treatment Launches Partnership With Destination Hearing 2Bed Bugs Cost Alton Housing Authority $35,000; New Help, How to Kill Bed Bugs With Less Expense, Introduced by My Cleaning Products 2Monitoring Protein Synthesis One Codon at a Time Through Ribosome Profiling, a Webinar Hosted by Xtalks 2
... Cynvec LLC, a privately-held,biopharmaceutical company focused on developing ... the Sindbis viral vector, announced today,that it has ... effective immediately, to lead the company,s next phase ... Mr. Stonebanks will serve on Cynvec,s Board,of Directors., ...
... , - Revenues Expected to be up 26%, ... Site Limited ("The Binding Site" or the "Company"), a,privately-owned ... the year ended 30th September 2008. The full audited,results ... are expected to be GBP38.9 million, representing sales growth,of ...
... - Fourth quarter constant currency revenue growth of 12.9 ... percent, constant currency), and improving profitability reflects ... annual financial guidance for fiscal year 2009, BATESVILLE, ... ), announced unaudited financial results for its fiscal,fourth quarter ...
Cached Biology Technology:Cynvec LLC(SM) Appoints Former Johnson & Johnson Executive Frank D. Stonebanks as President and Chief Executive Officer 2Cynvec LLC(SM) Appoints Former Johnson & Johnson Executive Frank D. Stonebanks as President and Chief Executive Officer 3The Binding Site Announces Trading Update for Year Ended September 30th 2008 2The Binding Site Announces Trading Update for Year Ended September 30th 2008 3Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 2Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 3Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 4Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 5Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 6Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 7Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 8Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 9Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 10Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 11Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 12Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 13Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 14Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 15Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 16Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 17Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 18Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 19
(Date:5/21/2013)... the path of insulin action in cells in precise ... for understanding what goes wrong in diabetes. , ... David James from Sydney,s Garvan Institute of Medical Research, ... the prestigious journal Cell Metabolism . , First ... important role in the body because it helps us ...
(Date:5/20/2013)... University of Minnesota Medical School researchers from the Masonic ... University,s Brain Tumor Program, have developed a new mouse ... allow them to discover new genes and gene pathways ... published this week in the journal Nature Genetics ... in the lab of David Largaespada, Ph.D., professor in ...
(Date:5/20/2013)... URBANA - A National Science Foundation (NSF) planning grant ... Drying (CARD), a joint program of the University of ... Worcester, Mass. , "CARD will be devoted to research ... other agricultural products; forestry and paper products; chemical products; ... I professor of food science and human nutrition and ...
Breaking Biology News(10 mins):Insight into the dazzling impact of insulin in cells 2Insight into the dazzling impact of insulin in cells 3U of M researchers develop model for better testing, targeting of MPNST 2NSF approves planning grant for Center for Advanced Research in Drying 2
... WEST LAFAYETTE, Ind. - Bacteria are ... and cause disease - by manipulating a natural cellular process. , ... team that revealed how a pair of proteins from the bacteria ... protein in order to divert raw materials within the cell for ...
... Sweden, have used advanced light microscopy to show that a ... what it is mixed with. This may determine whether it ... able to identify specific cells and proteins in the skin ... understanding of the mechanisms behind contact allergy", says Carl Simonsson ...
... Scientists studying a unique collection of human skulls have ... have occurred independently through separate evolutionary events may have ... of Manchester and Barcelona examined 390 skulls from the ... human skull is highly integrated, meaning variation in one ...
Cached Biology News:Purdue scientists reveal how bacteria build homes inside healthy cells 2Purdue scientists reveal how bacteria build homes inside healthy cells 3Interactions between substances determine allergenic potential 2Human skull study causes evolutionary headache 2
... An antibody made to the C-terminal VMAT2 ... kDa in postnuclear supernatants of CHO transfected ... cells (2). Some additional bands, both higher ... and remain unaffected by the inclusion of ...
... Metalloproteinase-2, Hinge Region By immunoblotting the antibody ... It reacts with free MMP-2 or MMP-2 ... buffered aqueous glycerol solution Solution in ... containing 50% glycerol and 15 mM sodium ...
Acetylcholinesterase from human and monkey....
...
Biology Products: